BofA's Geoff Meacham on Eli Lilly on Q4 results: The story has changed to diabetes and obesity

Geoff Meacham, Bank of America Securities senior pharmaceuticals analyst, joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro.